BLGO · Biolargo, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $657.0K | - | $731.0K | $1.36M | $1.78M | - | $1.24M | $2.88M | $2.51M | - |
| Gross Profit | $458.0K | - | $372.0K | $1.42M | $1.49M | - | $1.72M | $2.14M | $2.25M | - |
| R&D | $907.0K | - | $615.0K | $535.0K | $791.0K | - | $690.0K | $623.0K | $784.0K | - |
| SG&A | $2.75M | - | $3.09M | $2.69M | $2.56M | - | $2.09M | $2.40M | $2.23M | - |
| Total Operating Expenses | $3.66M | - | $7.55M | $3.22M | $3.35M | - | $2.97M | $2.38M | $3.01M | - |
| D&A | $34.0K | - | $34.0K | $36.0K | $42.0K | - | $39.0K | $26.0K | $36.0K | - |
| Operating Income | ($3.20M) | - | ($7.18M) | ($1.80M) | ($1.86M) | - | ($1.06M) | ($890.0K) | ($763.0K) | - |
| Interest Expense | $188.0K | - | $144.0K | $80.0K | $65.0K | - | - | $2.0K | $12.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($2.29M) | - | ($6.48M) | ($1.19M) | ($1.16M) | - | ($537.0K) | ($441.0K) | ($410.0K) | - |
| EPS - Basic | ($0.01) | - | ($0.02) | ($0.00) | ($0.00) | - | ($0.00) | ($0.00) | ($0.00) | - |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.12M | $3.88M | $4.55M | $3.47M | $2.56M | $3.55M | $3.88M | $4.76M | $4.34M | $3.54M |
| Accounts Receivable | $730.0K | $615.0K | $761.0K | $1.74M | $4.21M | $3.17M | $3.21M | $2.10M | $2.47M | $2.61M |
| Inventory | $292.0K | $310.0K | $409.0K | $444.0K | $310.0K | $330.0K | $238.0K | $176.0K | $251.0K | $153.0K |
| Accounts Payable | $838.0K | $1.01M | $789.0K | $1.18M | $1.15M | $826.0K | $1.56M | $1.47M | $1.66M | $1.21M |
| Current Assets | $5.45M | $5.11M | $5.78M | $9.19M | $7.22M | $7.14M | $7.39M | $7.11M | $7.18M | $6.36M |
| Total Assets | $8.56M | $8.31M | $9.13M | $12.50M | $10.51M | $10.51M | $10.30M | $10.05M | $9.82M | $8.21M |
| Current Liabilities | $4.93M | $5.06M | $3.45M | $4.08M | $3.37M | $2.65M | $3.20M | $3.01M | $3.40M | $2.71M |
| Long-term Debt | - | $2.08M | - | - | - | $1.08M | $180.0K | $184.0K | $284.0K | $289.0K |
| Total Liabilities | $8.75M | $6.79M | $5.92M | $6.44M | $5.42M | $4.46M | $4.32M | $4.16M | $4.67M | $4.00M |
| Stockholders' Equity | $1.79M | $4.04M | $6.58M | $8.76M | $7.61M | $8.85M | $8.58M | $6.00M | $8.12M | $6.84M |
| Retained Earnings | ($163.57M) | ($161.28M) | ($158.33M) | ($151.85M) | ($150.66M) | ($149.50M) | ($148.49M) | ($147.95M) | ($147.51M) | ($147.10M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.92M) | - | - | - | ($1.83M) | - | - | - | $481.0K | - |
| Investing Cash Flow | ($32.0K) | - | - | - | $0 | - | - | - | ($863.0K) | - |
| Financing Cash Flow | $3.19M | - | - | - | $866.0K | - | - | - | $1.08M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -26.7% | - | -71.0% | -9.5% | -11.0% | - | -5.2% | -4.4% | -4.2% | - |
| Return on equity | -128.0% | - | -98.5% | -13.6% | -15.2% | - | -6.3% | -7.3% | -5.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.10 | 1.01 | 1.67 | 2.25 | 2.14 | 2.70 | 2.31 | 2.36 | 2.11 | 2.35 |
| Quick ratio | 1.04 | 0.95 | 1.55 | 2.14 | 2.05 | 2.57 | 2.24 | 2.30 | 2.03 | 2.29 |
| Cash ratio | 0.84 | 0.77 | 1.32 | 0.85 | 0.76 | 1.34 | 1.21 | 1.58 | 1.27 | 1.31 |
| Leverage | ||||||||||
| Debt / Equity | - | 0.51 | - | - | - | 0.12 | 0.02 | 0.03 | 0.03 | 0.04 |
| Debt / Assets | - | 0.25 | - | - | - | 0.10 | 0.02 | 0.02 | 0.03 | 0.04 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -17.0x | - | -49.9x | -22.5x | -28.6x | - | - | -445.0x | -63.6x | - |
| Equity multiplier | 4.80 | 2.06 | 1.39 | 1.43 | 1.38 | 1.19 | 1.20 | 1.67 | 1.21 | 1.20 |
| Liabilities / Assets | 1.02 | 0.82 | 0.65 | 0.52 | 0.52 | 0.42 | 0.42 | 0.41 | 0.48 | 0.49 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | 2.25 | - | 1.79 | 3.05 | 5.75 | - | 5.20 | 16.35 | 10.02 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 162d | - | 204d | 120d | 64d | - | 70d | 22d | 36d | - |
| Days payable outstanding | 466d | - | 394d | 317d | 237d | - | 461d | 187d | 241d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -69.2% | - | -78.4% | -33.5% | -33.7% | - | 20.0% | 160.9% | 24.1% | - |
| Operating income growth (YoY) | -72.1% | - | -576.7% | -102.5% | -144.0% | - | 31.0% | 42.9% | -60.0% | - |
| Net income growth (YoY) | -97.9% | - | -1106.5% | -170.3% | -181.7% | - | 55.3% | 66.8% | -66.0% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -76.5% | -54.3% | -23.3% | 45.9% | -6.2% | 29.3% | 21.3% | -18.5% | 27.1% | 40.3% |
Peer comparison
Same SIC group: Chemicals & Allied Products
Comparing BIOLARGO against the 5 most active filers in the same SIC group.